Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | MOGAT2 | Q3SYC2 | 4/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.35 |
| ▸ | PPARD | Q03181 | 5/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736204 | 1.00 | KDM1A (0.38) | KDM1ACYP2C9MOGAT2PTPN11FFAR1 | |
| SCHEMBL12736200 | 1.00 | KDM1A (0.38) | KDM1ACYP2C9MOGAT2PTPN11FFAR1 | |
| SCHEMBL12736197 | 0.99 | KDM1A (0.38) | KDM1ACYP2C9MOGAT2PTPN11FFAR1 | |
| SCHEMBL12736189 | 0.97 | KDM1A (0.39) | KDM1ACYP2C9MOGAT2FFAR1PPARD | |
| SCHEMBL12740798 | 0.93 | PPARD (0.38) | KDM1ACYP2C9MOGAT2PTPN11FFAR1 | |
| SCHEMBL12740795 | 0.93 | PPARD (0.38) | KDM1ACYP2C9MOGAT2PTPN11FFAR1 | |
| SCHEMBL12740796 | 0.93 | PPARD (0.38) | KDM1ACYP2C9MOGAT2PTPN11FFAR1 | |
| SCHEMBL14766142 | 0.93 | FFAR1 (0.39) | KDM1AFFAR1PPARDFFAR4 | |
| SCHEMBL12740794 | 0.92 | PPARD (0.39) | KDM1ACYP2C9MOGAT2PTPN11FFAR1 | |
| SCHEMBL14766140 | 0.91 | FFAR1 (0.38) | KDM1AFFAR1PPARDFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | KDM1A 937/4885CYP2C9 2816/4885MOGAT2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.